This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
September 2026 quarter: revenue up 20.8%, profit after tax up 30.4%
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Midcap 150 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated quarter ended 30 September 2026: revenue was Rs 118,357 lakh, up 20.8%, and profit after tax Rs 33,588 lakh, up 30.4%, versus Rs 97,994 lakh and Rs 25,749 lakh a year earlier. Half-year ended 30 September 2026: revenue Rs 212,201 lakh and profit after tax Rs 57,306 lakh; operating cash flow was positive at Rs 31,144 lakh. Walker Chandiok was named statutory auditor from FY2027-28, pending shareholder approval.
Quarterly growth supports positive sentiment, but half-year profit includes Rs 4,209 lakh of tax-refund interest, so recurring earnings are lower.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹1,184 Cr | ₹979.9 Cr | +20.8% |
| Operating profit | ₹386.6 Cr | ₹317.8 Cr | +21.6% |
| Profit after tax | ₹335.9 Cr | ₹257.5 Cr | +30.4% |
| EBITDA margin | 34.0% | 34.5% | −0.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.